Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences (WVE)
NASDAQ:WVE
WVE Analyst Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
WVE Stock 12 Month Forecast
Average Price Target
$18.40
▲(179.21%Upside)
| Highest Price Target$26.00 | Average Price Target$18.40 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$7.5
Hold
13.81%
Upside
Reiterated
06/07/25
Wave Life Sciences' overall stock score is influenced primarily by financial challenges and valuation concerns. Despite positive corporate developments, significant operational and financial hurdles remain. Improvement in financial metrics and continued success in clinical trials are crucial for enhancing the stock's attractiveness.
Raymond James
$14
Buy
112.44%
Upside
Initiated
06/10/25
Mizuho Securities
$22
Buy
233.84%
Upside
Reiterated
06/09/25
Truist Financial
―
Buy
―
Reiterated
05/09/25
H.C. Wainwright
$22
Buy
233.84%
Upside
Reiterated
05/09/25
Leerink Partners
$24
Buy
264.19%
Upside
Reiterated
05/08/25
RBC Capital
$10→$9
Hold
36.57%
Upside
Reiterated
05/08/25
Wedbush
$18
Buy
173.14%
Upside
Reiterated
05/08/25
Cantor Fitzgerald
$10
Buy
51.75%
Upside
Initiated
04/28/25
B.Riley Financial
$22→$19
Buy
188.32%
Upside
Reiterated
04/10/25
JonesTrading
$20
Buy
203.49%
Upside
Reiterated
03/26/25
We think accelerated approval is likely, given sustained dystrophin expression and clean safety profile is a key differentiator from other DMD assets. WVE expects to submit multiple CTAs for other exon skipping programs in 2026. These include 52, which should give us a chance to see how WVE stacks up against Dyne (DYN, Avidity (RNA, Not Rated).
Jefferies
$26
Buy
294.54%
Upside
Reiterated
03/26/25
J.P. Morgan
$20→$21
Buy
218.66%
Upside
Reiterated
03/04/25
Wells Fargo
$22
Buy
233.84%
Upside
Assigned
01/13/25
Wave Life Sciences: Buy Rating Based on Promising Clinical Updates and RNA Editing AdvancementsWe think the multi-dose update could potentially further de-risk this asset. WVE is eligible to receive up to $525M in total milestones and tiered royalties on net sales for '006. More importantly, we see the RNA editing as a platform oppty with potential to provide non- dilutive capital. WVE plans to share new preclinical data from its hepatic and extra- hepatic RNA editing programs in 2025, and the company expects to initiate clinical development of additional RNA editing programs, including in 2026.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$7.5
Hold
13.81%
Upside
Reiterated
06/07/25
Wave Life Sciences' overall stock score is influenced primarily by financial challenges and valuation concerns. Despite positive corporate developments, significant operational and financial hurdles remain. Improvement in financial metrics and continued success in clinical trials are crucial for enhancing the stock's attractiveness.
Raymond James
$14
Buy
112.44%
Upside
Initiated
06/10/25
Mizuho Securities
$22
Buy
233.84%
Upside
Reiterated
06/09/25
Truist Financial
―
Buy
―
Reiterated
05/09/25
H.C. Wainwright
$22
Buy
233.84%
Upside
Reiterated
05/09/25
Leerink Partners
$24
Buy
264.19%
Upside
Reiterated
05/08/25
RBC Capital
$10→$9
Hold
36.57%
Upside
Reiterated
05/08/25
Wedbush
$18
Buy
173.14%
Upside
Reiterated
05/08/25
Cantor Fitzgerald
$10
Buy
51.75%
Upside
Initiated
04/28/25
B.Riley Financial
$22→$19
Buy
188.32%
Upside
Reiterated
04/10/25
JonesTrading
$20
Buy
203.49%
Upside
Reiterated
03/26/25
We think accelerated approval is likely, given sustained dystrophin expression and clean safety profile is a key differentiator from other DMD assets. WVE expects to submit multiple CTAs for other exon skipping programs in 2026. These include 52, which should give us a chance to see how WVE stacks up against Dyne (DYN, Avidity (RNA, Not Rated).
Jefferies
$26
Buy
294.54%
Upside
Reiterated
03/26/25
J.P. Morgan
$20→$21
Buy
218.66%
Upside
Reiterated
03/04/25
Wells Fargo
$22
Buy
233.84%
Upside
Assigned
01/13/25
Wave Life Sciences: Buy Rating Based on Promising Clinical Updates and RNA Editing AdvancementsWe think the multi-dose update could potentially further de-risk this asset. WVE is eligible to receive up to $525M in total milestones and tiered royalties on net sales for '006. More importantly, we see the RNA editing as a platform oppty with potential to provide non- dilutive capital. WVE plans to share new preclinical data from its hepatic and extra- hepatic RNA editing programs in 2025, and the company expects to initiate clinical development of additional RNA editing programs, including in 2026.
Best Analysts Covering Wave Life Sciences
1 Month
xxx
Success Rate
7/14 ratings generated profit
Average Return
+6.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +6.00% per trade.
3 Months
xxx
Success Rate
20/50 ratings generated profit
Average Return
-2.84%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -2.84% per trade.
1 Year
Success Rate
10/14 ratings generated profit
Average Return
+27.67%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +27.67% per trade.
2 Years
xxx
Success Rate
8/14 ratings generated profit
Average Return
+18.90%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +18.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
WVE Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
6
15
17
19
10
Buy
5
5
5
5
2
Hold
0
1
2
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
21
24
27
14
Each month's total comprises the sum of three months' worth of ratings.
WVE Financial Forecast
WVE Stock Forecast FAQ
What is WVE’s average 12-month price target, according to analysts?
Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 18.40.
What is WVE’s upside potential, based on the analysts’ average price target?
Wave Life Sciences has 179.21% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is WVE a Buy, Sell or Hold?
Wave Life Sciences has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is Wave Life Sciences’s price target?
The average price target for Wave Life Sciences is 18.40. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $9.00. The average price target represents 179.21% Increase from the current price of $6.59.
The highest analyst price target is $26.00 ,the lowest forecast is $9.00. The average price target represents 179.21% Increase from the current price of $6.59.
What do analysts say about Wave Life Sciences?
Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of WVE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.